*Reflecting our continued growth and evolution, Asha Therapeutics is now First Atom Therapeutics - Redefining Medicine Atom-by-Atom. For more information please contact us at info@firstatomtx.com
Recent News & Updates
Targeting the most challenging diseases
First Atom's Pipeline of PRISM Platform™ Designed, Disease-Modifying Therapeutics
First Atom Therapeutics has successfully designed breakthrough therapeutics for diseases with high unmet medical need, including Amyotrophic Lateral Sclerosis, hereditary optic atrophies, and Parkinson's Disease, using First Atom's proprietary PRISM Platform™. Learn more about our pipeline medicines and active discovery programs.
Leveraging a Revolutionary Drug Design Technology Towards Changing Patient Outcomes
15+
New Chemical Entity Programs Designed
20+
Scientific
Collaborations
2
IND-stage Medicines aimed for clinic
5+
Drug Optimization
Projects
Strategic
Collaboration & Transformative Partnerships
The PRISM™ Design Platform - Tailored Design
of New Medicines
PRISM Platform™ is a revolutionary drug design technology that leverages zero-shot AI-integration for the atom-by-atom de novo design of new medicines. The PRISM Platform™ does not utilize any existing chemical structures for the development of new medicines. Instead, the PRISM Platform™ uses proprietary algorithms to enable the rational design of target specific compounds.
Dependent on existing compound libraries
Throughput-driven
Serendipitous
Misses cryptic pockets
10 compounds accessed
through screening
9
Constructs molecules from first principles
Insight-driven
Deterministic
Reveals latent structure
10 compounds accessed
through design
63
Design vs. Screening
Drug Screening Methods
PRISM Platform™ De Novo Design